What is the recommended starting dose of Strattera (atomoxetine) in a patient already taking Effexor (venlafaxine) and Wellbutrin (bupropion)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Starting Dose for Strattera (Atomoxetine) When Already on Effexor and Wellbutrin

Start atomoxetine at 40 mg once daily, then titrate to 60 mg after 7-14 days, and potentially to 80 mg if needed, with a maximum dose of 100 mg/day or 1.4 mg/kg/day (whichever is less). 1

Initial Dosing Strategy

The standard starting dose for atomoxetine is 40 mg once daily, regardless of concurrent antidepressant use 1. This conservative approach is particularly important when combining with venlafaxine (Effexor) and bupropion (Wellbutrin), as all three medications affect different neurotransmitter systems and require careful monitoring.

Titration Schedule

  • Week 1-2: Begin with 40 mg daily 1
  • Week 2-4: Increase to 60 mg daily if tolerated 1
  • Week 4+: May increase to 80 mg daily if needed for therapeutic effect 1
  • Maximum dose: Do not exceed 100 mg/day or 1.4 mg/kg/day, whichever is lower 1

The titration intervals of 7-14 days allow adequate time to assess tolerability and response before dose escalation 1.

Critical Safety Considerations with This Combination

Seizure Risk from Bupropion

  • Bupropion lowers the seizure threshold and requires gradual dose titration 1
  • The maximum safe dose for bupropion SR is 400 mg/day 2, 1
  • Ensure bupropion doses are not taken late in the day (second dose before 3 PM) to minimize insomnia 2

Drug Interaction Monitoring

  • This triple combination (atomoxetine + venlafaxine + bupropion) affects norepinephrine, serotonin, and dopamine systems simultaneously 1, 3
  • Monitor for increased agitation, as bupropion is activating 2
  • Watch for blood pressure elevations, as both venlafaxine and atomoxetine can increase blood pressure 4, 1

Absolute Contraindications

  • Active seizure disorder or history of seizures (due to bupropion) 1
  • Current MAOI use or within 14 days of MAOI discontinuation 1
  • Eating disorders (anorexia nervosa or bulimia) if on bupropion 1

Monitoring Parameters

  • Blood pressure: Check at baseline and regularly during titration, as both venlafaxine and atomoxetine can cause hypertension 4, 1
  • Neuropsychiatric symptoms: Monitor for increased agitation, anxiety, or mood changes 2, 1
  • Seizure precautions: Ensure no risk factors for seizures develop (alcohol withdrawal, benzodiazepine discontinuation) 1

Clinical Rationale for This Approach

The combination of atomoxetine (norepinephrine reuptake inhibitor), venlafaxine (serotonin-norepinephrine reuptake inhibitor), and bupropion (norepinephrine-dopamine reuptake inhibitor) provides complementary mechanisms of action 1, 3. Starting atomoxetine at the standard 40 mg dose allows assessment of tolerability in the context of existing antidepressant therapy without overwhelming the patient's system 1.

Common Pitfalls to Avoid

  • Do not start at higher doses thinking the patient is already on antidepressants—the standard 40 mg starting dose applies 1
  • Do not rush titration—allow the full 7-14 days between dose increases to assess tolerability 1
  • Do not exceed maximum doses of any medication in the regimen to minimize adverse effects and seizure risk 2, 1
  • Do not ignore timing of bupropion doses—late-day dosing significantly increases insomnia risk 2

References

Guideline

Combination Therapy with Atomoxetine and Bupropion

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Bupropion Dosing and Administration

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.